Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - Compugen reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of +22.22% [1] - The company posted revenues of $1.89 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 14.43% and down from $17.13 million year-over-year [2] - Compugen shares have increased by approximately 5.9% since the beginning of the year, underperforming the S&P 500's gain of 14.4% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.09 on revenues of $4.91 million, and for the current fiscal year, it is -$0.34 on revenues of $12.34 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Compugen belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Compugen's stock performance [5][6]